Evidence map›Paper›PMID 39706258›Full record

ArticleJournal of vascular surgery. Venous and lymphatic disorders2025

Safety assessment of cyanoacrylate closure for treatment of varicose veins in a large-scale national survey in Japan.

Michihisa Umetsu, Masayuki Hirokawa, Eri Fukaya, Eiichi Teshima, Hitoshi Kusagawa, Toshiya Nishibe, Makoto Mo, Tomohiro Ogawa

Abstract readMulticenter Study
In one paragraph

Article in Journal of vascular surgery. Venous and lymphatic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michihisa UmetsuDivision of Vascular Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Japan. Electronic address: mumetsu@tohoku.ac.jp.
Masayuki HirokawaOchanomizu Vascular and Vein Clinic, Tokyo, Japan.
Eri FukayaDivision of Vascular Surgery, Stanford School of Medicine, Palo Alto, CA.
Eiichi TeshimaFukuoka Wajiro Hospital, Vascular and Endovascular Surgery, Fukuoka, Japan.
Hitoshi KusagawaMatsusaka Ohta Clinic, Matsusaka, Japan.
Toshiya NishibeDepartment of Medical Management and Informatics, Hokkaido Information University, Ebetsu, Japan.
Makoto MoDepartment of Cardiovascular Surgery, Yokohama Minami Kyosai Hospital, Yokohama, Japan; Department of Surgery, Yokohama City University, Yokohama, Japan; Japanese Society of Phlebology, Tokyo, Japan.
Tomohiro OgawaDepartment of Cardiovascular Surgery, Fukushima Dai-Ichi Hospital, Fukushima, Japan; Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCyanoacrylate closure (CAC) is a minimally invasive technique for treating axial venous reflux. However, the incidence of serious adverse events (AEs) related to CAC is concerning. With an increasing number of patients undergoing CAC and insufficient safety data in Japan, this study aimed to investigate the safety profile of CAC, focusing on the types and incidence of AEs.

methodsA nationwide survey was conducted by the Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins between November 2023 and December 2023. Data were collected from 1017 institutions, covering 24,209 patients who underwent CAC at 335 institutions between January 2020 and October 2023. Thromboembolism, phlebitis, hypersensitivity reactions, granuloma formation, infection, bleeding, death, and need for glue resection were documented as unfavorable events or outcomes.

resultsVenous thromboembolism developed in 142 patients (0.59%). Pulmonary embolism, proximal deep vein thrombosis, and ablation-related thrombus extension developed in 3 (0.01%), 9 (0.04%), and 95 (0.39%) patients, respectively. Localized phlebitis that required additional treatment was observed in 1656 patients (6.8%). Of the localized hypersensitivity cases, 960 (58%) required oral antihistamines and 268 (16%) required oral and/or intravenous steroids. Furthermore, 65 patients (0.27%) developed systemic hypersensitivity that required systemic steroids. No patients developed a stroke or anaphylaxis. One patient died owing to pulmonary embolism. Glue resection was performed in nine patients with delayed infection (n = 4), hypersensitivity reactions (n = 4), or a foreign body granuloma (n = 1). The incidence of hypersensitivity reactions was similar among institutions. However, the incidence of thrombosis-related events significantly differed between the high-volume and low-volume institutions. The incidence of proximal deep vein thrombosis (0.13% vs 0.01%; P < .001; odds ratio, 12.5; 95% confidence interval, 2.6-60.3) and ablation-related thrombus extension (0.73% vs 0.30%; P < .001; odds ratio, 2.5; 95% confidence interval, 1.66-3.77) was significantly higher in low-volume institutions than in high-volume centers.

conclusionsA nationwide survey of CAC for varicose veins in Japan demonstrated that it was a safe procedure with a low rate of serious AEs, such as venous thromboembolism. However, hypersensitivity reactions requiring steroid administration and systemic allergic reactions were observed in some patients.

Indexed as

CyanoacrylatesEndovascular ProceduresVaricose VeinsAdultAgedAged, 80 and overDrug HypersensitivityFemaleHealth Care SurveysHumansIncidenceJapanMaleMiddle AgedRetrospective StudiesRisk AssessmentCyanoacrylatesAdverse eventComplicationCyanoacrylate closureNational surveyVaricose vein

Identifiers

PMID39706258
PMCPMC12014294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.